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Abstract
Objective: The objective of the selective EBM review is to determine whether or not
Rabeprazole is a safe treatment for GERD in children less than sixteen years old.
Study Design: Review of three randomized controlled studies. All three studies were published
in English between 2007-2013.
Data Sources: Three randomized, un-blinded, controlled studies found using Medline and
PubMed
Outcomes Measured: Each trial measured the adverse events that occurred with the use of
Rabeprazole for the treatment of GERD in children less than sixteen years of age. This was done
by using subjective reporting of treatment-emergent adverse events (TEAE’s). Differences in the
frequency of Treatment Emergent Signs and Symptoms (TESS) between the two treatment
groups analyzed using the Fischer exact test and/or an appropriate nonparametric procedure.
Results: Three un-blinded RCT’s were included in this review and it was found that Rabeprazole
did not lead to any significant life-threatening treatment-emergent adverse events (TEAE’s) in
patients less than sixteen years of age. The most common adverse events were headache,
nausea, cough, vomiting, abdominal pain, and diarrhea.
Conclusions: Based on these three trials, Rabeprazole is a safe treatment for GERD in children
less than sixteen years of age. Each study showed a significant improvement of symptoms
without any serious side effects when using Rabeprazole
Key Words: Rabeprazole, GERD, and children
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INTRODUCTION
Gastroesophageal Reflux “GER” is the passage of gastric contents into the esophagus
with or without regurgitation or vomiting.1 Physiologic “GER” is a very common and normal
process in infants and slightly older children, however when this process becomes chronic and
GERD develops it can lead to more serious symptoms such as swallowing difficulties that lead to
weight loss, failure to thrive, and respiratory problems.1 If these symptoms are not treated in
time it can lead to long-term complications and a decreased quality of life for these children. 1
This paper evaluates three randomized controlled trials comparing the safety of Rabeprazole
for the treatment of children less than sixteen years old with GERD.
Reflux is an extremely common complaint from patients with about 18-27% of North
America’s population being effected.6 So, because of its prevalence in this country it is relevant
to the Physician Assistant profession. “GER” occurs in almost 100% of infants and is a normal
process that typically resolves by the age of one.1 Although, it is thought that approximately 222% of children between the ages of 3-18 years have GERD symptoms, but the exact statistics
remain unknown.1 The annual medical cost per patient in 2006 was $6,878.6 Medical services
which include doctor visits, hospitalizations, ER costs, and lab costs totaled to about $4,200,
and prescription drug costs were estimated to be about $922.6 Gastrointestinal visits to the
hospital, with GERD being the most common, represent about 8.9 million hospital visits each
year. 4 Outpatient endoscopy’s used to diagnose GERD cost about $32.4 billion dollars each
year.4
The exact cause of GERD is unknown however there are many contributing factors that
exacerbate symptoms. These factors include smoking, alcohol, obesity, eating large meals,
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eating too soon or right before bed, hiatal hernias, pregnancy and diabetes. 5 Certain foods can
increase GERD symptoms as well, these include chocolate, fried or fatty foods, caffeine, acidic
foods such as fruits and tomatoes, and spicy foods.5
Typically the first line treatment for GERD involves lifestyle modifications.5 These
modifications include changes such as no food within three hours of bed, no large meals, raising
the head of the bed, weight loss, avoiding alcohol, smoking cessation.5 Also it is recommended
that patients avoid the foods previously mentioned as they are known to increase GERD
symptoms.5 If these lifestyle modifications do not provide adequate relief for the patient the
next step is the use of antacids, H2 blockers, or Proton Pump Inhibitors.5 There are surgical
options for treatment such as fundoplication, although these are usually reserved as a last
resort.5
While there is currently no cure for GERD, all of the lifestyle modifications and medical
treatment options listed above have seemed to improve symptoms in adult patients with GERD.
This topic is being proposed to address the safety of this treatment option in younger
populations to hopefully reduce symptoms and improve their quality of life.

OBJECTIVE
The objective of this systematic review is to determine whether or not Rabeprazole is a safe
treatment for GERD in children less than sixteen years of age.
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METHODS
Three un-blinded randomized controlled trials were used in this study. The population includes
patients ages 1-16 years of age with a diagnosis of GERD. The intervention was the proton
pump inhibitor Rabeprazole. All three of the studies were divided into two parts and the two
parts were compared for TEAE’s. Throughout the first section of the Haddad and Zannikos
studies the patients were given approximately 0.14 mg/kg of Rabeprazole which is comparable
to the lowest effective adult dose of the medication which is 10 mg, and they were observed
for adverse events or reactions to the medications.1,3 Then during the second part of the
Haddad and Zannikos studies patients were randomized into two different groups and given a
dose of Rabeprazole from the 0.5-1.0 mg/kg range.1,3 In the first part of the James study the
patients received the lowest effective 10 mg dose of Rabeprazole and observed for adverse
events or reactions to the medication.2Then during the second part of the James study the
patients were randomized into two different groups and they either received another 10 mg
dose or a higher 20 mg dose of Rabeprazole and observed for adverse events or reactions to
the medications.2
Key words used to research these articles were Rabeprazole, GERD, and children. All
three articles were researched by the author and obtained through either Medline or PubMed.
The articles were published in English and published in peer-reviewed journals. These articles
were chosen based on the types of studies and relevance to the clinical question. The inclusion
criteria for this search included randomized controlled trials in which the outcomes directly
benefited the patient population in the selected age range. Exclusion criteria included patients
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over the age of sixteen, pregnant or lactating patients, patients with allergies to PPI’s, H. pylori
infection, or previous acid lowering surgery or previous esophageal/gastric surgery. The
statistics used and reported were numbers needed to treat (NNT), relative risk reduction (RRR),
absolute risk reduction (ARR), and p-values. Table 1 displays the characteristics and
demographics included in these studies.
Table 1 – Demographics and Characteristic of included studies
Study

Type

# Pts

Age
(yrs)

Inclusion
criteria

Exclusion criteria

W/D

Interventions

Haddad1 (2013)

RCT

127

1-11

Pts ages 1-11
who have
endoscopically
proven GERD

-Allergies to PPI’s
-H. Pylori infection

19

Rabeprazole
10 mg and 20
mg once daily
orally

James2 (2007)

RCT

19

12-16

Pts ages 12-16
with a clinical
dx of GERD
and minimum
body weight of
30 kg

1

Rabeprazole
10 mg and 20
mg once daily
orally

Zannikos3 (2011)

RCT

24

1-11

Pts ages 1-11
with GERD and
a minimum

-evidence of other
significant health
condition
-pregnant/lactating
females
-unwilling to refrain
from
smoking/drinking
alcohol
-drug
allergy/sensitivity to
PPI’s
-significant
viral/bacterial
infection within 1
month of screening
-definitive acid
lowering surgery or
previous
esophageal/gastric
surgery
-history of or current
clinically significant
medical illness
-H. pylori infection

0

Rabeprazole
0.5 mg or 1
mg once daily
orally
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body weight of
10 kg

-sensitivity to PPI’s

OUTCOMES MEASURED
The outcomes measured in this study were the presence and severity of treatment-emergent
adverse events (TEAE’s) related to the use of Rabeprazole.1,2,3 The patients involved in each of
these studies were assessed at each study visit for TEAE’s. These assessments included physical
examinations, vital signs, 12-lead ECG, and lab tests such as hematology, chemistry, and
urinalysis were done.1,2,3 Most of the TEAE’s in this study were discovered through subjective
reporting by the patients themselves.1,2,3 Differences in frequency of treatment emergent signs
and symptoms (TESS) between the two treatment groups were analyzed using the Fischer exact
test and/or an appropriate nonparametric procedure.2

RESULTS
This review examined three RCT’s including children ages 1-16 with a known history of
GERD and then compared the use of a low dose of Rabeprazole in the first part of each study to
a higher dose of Rabeprazole in the second part of each study for the treatment of GERD. The
results of all three studies was reported as dichotomous data and therefore allowed examiners
to assess the safety of the medication and any adverse events.1,2,3
In the James study there were a total of twenty-four subjects that enrolled in and
completed the study.2 Those patients with evidence of other significant health conditions,
pregnant/lactating patients, patients unwilling to refrain from smoking or drinking alcohol
during the study, patients with drug allergies or sensitivities to PPI’s, patients with significant
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viral or bacterial infection within one month of the screening period, patients who have had
definitive acid lowering surgery or previous esophageal or gastric surgery were excluded from
the study.2 The subjects were separated into two groups based on their ages (12 - <14 years
and 14-16 years) and then randomized to receive either a 10 mg or 20 mg dose of Rabeprazole
during the second part of this study.2 Those subjects who fell into the 12- <14 years range were
considered the control group and were given 10mg doses of Rabeprazole.2 Those subjects who
fell into the 14-16 years range were considered the experimental group and were given 20mg
doses of Rabeprazole.2 No deaths or serious adverse events (SAE’s) were reported during this
study, and there were also no adverse events which led to patients withdrawing from the
study.2 The incidence or CER of treatment emergent signs and symptoms in the control group
was 50%.2 The incidence or EER of treatment emergent signs and symptoms in the
experimental group was 41.7%.2 Headache (16.7%) and nausea (8.3%) were the most common
adverse events reported by subjects in this study.2 The incidence of TESS that were considered
to be related to the study were not however, considered to be clinically significant by the
examiners.2 The relative risk ratio (RRR) was calculated to be -16.6%.2 This means that those
subjects in the experimental group taking the higher dose of Rabeprazole have a 16.6% higher
risk of developing an adverse event versus those in the control group taking the lower dose.
The absolute risk reduction (ARR) was calculated to be -8.3%.2 This means that of those taking
in the experimental group taking the higher dose of Rabeprazole, 8.3% more will develop an
adverse event compared to those in the control group taking the lower dose. The numbers
needed to harm (NNH) was calculated to be -12.2 This means that for every 12 patients taking
the higher dose of Rabeprazole, 1 fewer would experience an adverse event.
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In the Haddad study, patient’s ages ranged from 1-11 years of age.1 The subjects were
divided by weight into two cohorts; a low-weight cohort (6-14.9 kg) and a high weight cohort
(>15 kg) .1 The low weight cohort was the control group and the high weight cohort was the
experimental group. These patients were then randomized to receive 5-10 mg of Rabeprazole
in the low-weight cohort and 10-20 mg of Rabeprazole in the high-weight cohort.1 Those
patients with H. Pylori infection and allergies to PPI’s were excluded from the study.1 The
incidence or CER of TEAE’s in the control group of this study was 77.5%.1 The incidence or EER
of TEAE’s in the experimental group of this study was 74.7%.1 The most common reported
TEAE’s were vomiting, cough, abdominal pain.1 There were no trends of TEAE’s or clinically
relevant changes seen in this study.1 The relative risk ratio (RRR) was calculated to be -3.6%.1
This means that those patients in the experimental group taking the higher doses of
Rabeprazole have a 3.6% higher risk of developing an adverse event versus those in the control
group. The absolute risk reduction (ARR) was calculated to be -2.8, which represents that of
those in the experimental group taking the higher dose of Rabeprazole, 2.8% more will develop
an adverse event compared to those in the control group taking the lower dose. The numbers
needed to harm(NNH) was calculated to be -35.1 This means that for every 35 patients taking
the higher dose of Rabeprazole, 1 fewer would experience an adverse.
In the Zannikos study, patient’s ages ranged from 1-11 years of age.3 “Eight patients
received 0.14 mg/kg of Rabeprazole during part one of the study.3 During part two of this study
11 patients were randomized to receive 0.5 mg/kg of Rabeprazole and 9 patients were
randomized to receive approximately 1 mg/kg of Rabeprazole.”3 Patients with evidence of
other significant health conditions, with H. Pylori infection, and those patients with sensitivity
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or allergies to PPI’s were excluded from the study.3 There were no deaths reported during this
study.3 One patient withdrew from the study on day five; she was diagnosed with moderate
viral gastritis on day four and developed a volvulus on day seven.3 These events were not
considered to be related to the study.3 The incidence or CER of TEAE’s in the control group of
this study was 81.8%.3 The incidence or EER of treatment TEAE’s in the experimental group of
this study was 77.8%.3 “Most of the TEAE’s were mild in severity and not considered to be
related to the study drug.”3 Vomiting (10.7%) was the most commonly reported adverse event
reported by subjects in this study.3 There were no trends of TEAE’s or clinically relevant changes
seen in this study.3 The relative risk ratio (RRR) was calculated to be -4.9%.3 This means that
those in the experimental group taking the higher doses of Rabeprazole have a 4.9% higher risk
of developing an adverse event versus those in the control group who received the lower dose.
The absolute risk ratio (ARR) was calculated to be -4% which means that of those in the
experimental group taking the higher dose of Rabeprazole 4% more will develop an adverse
event compared to those in the control group who took the lower dose. 3 The numbers needed
to harm (NNH) was calculated to be -25. This means that for every 25 people taking the higher
dose of Rabeprazole 1 fewer would experience an adverse event.
Table 2. Treatment Effects

STUDY

P-value

CER

EER

RRR

ARR

NNH

James

P = <0.001

42%

38%

-9.52%

-4%

-25

Haddad

P = <0.001

42%

38%

-9.52%

-4%

-25

Zannikos

P = <0.001

81.8%

77.8%

-4.9%

-4%

-25
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DISCUSSION
Rabeprazole is a proton pump inhibitor indicated for the use of duodenal ulcers, GERD,
H. Pylori eradication, and hypersecretory conditions like Zollinger-Ellison syndrome.8 Two off
label uses of Rabeprazole include the maintenance of healing and prevention of Duodenal
ulcers as well as the treatment and prevention of NSAID-induced ulcers.8 The only
contraindication to the use of Rabeprazole is if the patient has a hypersensitivity to
Rabeprazole, substituted benzimidazoles, or any other component of the formulation. 8 There
are several warnings/precautions regarding the use of Rabeprazole. “The use of PPI’s may
increase the risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized
patients.”8 Because of this, it is recommended that patients use the lowest dose of the
medication for the shortest duration appropriate for the condition being treated. 8 There is
increased risk of osteoporosis-related bone fractures with PPI therapy.8 It is recommended that
those patients on high dose (multiple daily doses) or long-term therapy (one year or longer)
should be monitored.8 Also, PPI’s are known to diminish the therapeutic effect of Clopidogrel
and should be avoided in patients taking Clopidogrel.8
While Rabeprazole has been extensively studied in adults, these are the first studies
published investigating the use of Rabeprazole in children ages 1-16 years old.1,2,3 Prior to these
studies, other PPI’s were proven effective in this patient population, and therefore it was not
ethical to include a placebo arm to assess the spontaneous response rate. 1,2,3 While this was a
major limitation to these studies the association between an improved endoscopic score and
improved clinical symptom score suggest that a placebo effect was not a major determining
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factor in the outcomes.1,2,3 No deaths were reported during any of these studies, and “no doseresponse relation was observed with respect to TEAE’s”.1,2,3 Overall the number and the rate of
TEAE’s commonly associated with Rabeprazole treatment were similar across all of the dose
groups. 1,2,3

CONCLUSION
This review and the chosen studies showed that Rabeprazole is a safe treatment for
GERD in children 1-16 years of age. No serious or life-threatening adverse events were reported
related to the use of Rabeprazole during these studies, and patient’s quality of life was
improved. Further studies should be double-blinded studies and would be more beneficial if
included a larger sample size. In the future, the development of a concrete scale for assessing
the TEAE’s involved with the use of PPI’s would be beneficial. Also, future research should
longer treatment durations to more definitively evaluate the benefits versus the risks of
treating GERD with Rabeprazole in this younger population.

Applegarth 13
Rabeprazole & GERD

REFERENCES
1. Haddad I. ea. Efficacy and safety of rabeprazole in children (1-11) years with
gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr. 2013;57(6):798-807.
2. James L, Walson P, Lomax K, et al. Pharmacokinetics and tolerability of rabeprazole
sodium in subjects aged 12 to 16 years with gastroesophageal reflux disease: An openlabel, single- and multiple-dose study. Clin Ther. 2007;29(9):2082-2092. doi:
10.1016/j.clinthera.2007.09.007.
3. Zannikos PN, Doose DR, Leitz GJ, et al. Pharmacokinetics and tolerability of rabeprazole
in children 1 to 11 years old with gastroesophageal reflux disease. J Pediatr
Gastroenterol Nutr. 2011;52(6):691-701. doi: 10.1097/MPG.0b013e318207834d;
10.1097/MPG.0b013e318207834d.
4. Zamosky, L. Treatment of GERD Evolving: Newer guidelines to save system
money. Medical Economics Business of Health. 2013. Accessed September 30, 2014.
5. Simic, J. Acid Reflux Disease (GERD). E Medicine Health.
http://www.emedicinehealth.com/acid_reflux_disease_gerd/page9_em.htm. Published
August 28, 2014. Accessed October 2, 2014.
6. Frandzel S. Direct and indirect costs of GERD examined in analysis of U.S. employee database.
Gastroenterology and Endoscopy News Web site.
http://www.gastroendonews.com/ViewArticle.aspx?d_id=187&a_id=5899. Published October
2006. Updated December 12, 2014. Accessed October, 2, 2014.

7. Rabeprazole. In Lexicomp. Hudson, OH. Lexicomp.
http://online.lexi.com.ezproxy.pcom.edu:2048/lco/action/doc/retrieve/docid/patch_f/7
604. Accessed November 5, 2014.

